Asan Medical Center | Clinical Trial Center
Status and phase
Conditions
Treatments
About
This study aims to assess objective response rate of modified FOLFIRINOX in advanced urachaus cancer.
Patients with locally advanced, recurrent, or metastatic urachal carcinoma of bladder, urachal will be enrolled this study.
Modified version of FOLFIRINOX(Oxaliplatin 85 mg/m 2, Leucovorin 400mg/m2 , irinotecan 150mg/m2 and 5-FU 2400mg/m2) with prophylactic pegateograstim will be continued till progression, unacceptable toxicity, or till 12 cycles (24 weeks). Study drugs can be administered after 12 cycles to the subjects with benefit from study medication.
Response evaluation will be done every 6 weeks.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Origin in the anterior wall or dome of the bladder Predominant invasion of muscularis or deeper tissues No obvious origin from the overlying urothelium (relative normal-looking urothelial mucosa) No primary adenocarcinoma elsewhere
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
35 participants in 1 patient group
Loading...
Central trial contact
Jae -Lyun Lee, Professor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal